Aviv Barzilai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aviv Barzilai has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Anna Lyakhovitsky
Department of Dermatology, Sheba Medical Center Ramat‐Gan Israel
4 shared publications - Gil Goldzweig
School of Behavioral Sciences, The Academic College of Tel-Aviv Jaffa, Tel-Aviv, Israel
3 shared publications - Lotan Levin
Division of Dermatology , Sheba Medical Center , Ramat-Gan , Israel , sheba.co.il
3 shared publications - Oz Segal
Department of Dermatology, Tel Aviv University, Tel Aviv, Israel
3 shared publications - Polina Geva
Sheba Medical Center 3 Department of Dermatology Ramat Gan
3 shared publications - Sharon Baum
Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv-Yafo, 69978, Israel; Dermatology Department, Sheba Medical Center, Tel HaShomer, Ramat Gan 52621, Israel
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 7383380
Response to Narrowband Ultraviolet B Phototherapy in Early Mycosis Fungoides Is Associated With Morphometric Histological Characteristics
Background and Objective: Narrowband ultraviolet B phototherapy is an established treatment for mycosis fungoides. Data on the factors that predict treatment efficacy are scarce. This study evaluated the association between morphometry of histological parameters and narrowband ultraviolet B efficacy in patients with early‐stage mycosis fungoides. Patients and Methods: Morphometric analyses of the degree of spongiosis and the number and size of lymphocytes in the epidermis were conducted retrospectively on biopsies from 57 patients with early‐stage mycosis fungoides treated with narrowband ultraviolet B phototherapy. Half of the patients achieved remission after 8 weeks and half did not. Results: TCR monoclonality, larger epidermal lymphocytes, and higher degree of spongiosis were associated with poor response ( p < 0.05) with a sensitivity of 0.82, 0.93, and 0.77, respectively, and a specificity of 0.52, 0.79, and 0.72, respectively. This association was still evident at the end of the phototherapy course. Larger lymphocytes in the epidermis correlated with TCR monoclonality ( p = 0.023). Spongiosis was independent of clonality. Conclusion: Morphometric analysis of histological parameters, such as spongiosis and lymphocyte size, is associated with response to narrowband ultraviolet B phototherapy in patients with early‐stage mycosis fungoides and may serve as markers for selecting appropriate, individualized treatment plans. Incorporating morphometry into biopsy analysis of early‐stage MF may also provide better diagnostic and prognostic accuracy.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 7383380
Open AccessResponse to Narrowband Ultraviolet B Phototherapy in Early Mycosis Fungoides Is Associated With Morphometric Histological Characteristics
Background and Objective: Narrowband ultraviolet B phototherapy is an established treatment for mycosis fungoides. Data on the factors that predict treatment efficacy are scarce. This study evaluated the association between morphometry of histological parameters and narrowband ultraviolet B efficacy in patients with early‐stage mycosis fungoides. Patients and Methods: Morphometric analyses of the degree of spongiosis and the number and size of lymphocytes in the epidermis were conducted retrospectively on biopsies from 57 patients with early‐stage mycosis fungoides treated with narrowband ultraviolet B phototherapy. Half of the patients achieved remission after 8 weeks and half did not. Results: TCR monoclonality, larger epidermal lymphocytes, and higher degree of spongiosis were associated with poor response ( p < 0.05) with a sensitivity of 0.82, 0.93, and 0.77, respectively, and a specificity of 0.52, 0.79, and 0.72, respectively. This association was still evident at the end of the phototherapy course. Larger lymphocytes in the epidermis correlated with TCR monoclonality ( p = 0.023). Spongiosis was independent of clonality. Conclusion: Morphometric analysis of histological parameters, such as spongiosis and lymphocyte size, is associated with response to narrowband ultraviolet B phototherapy in patients with early‐stage mycosis fungoides and may serve as markers for selecting appropriate, individualized treatment plans. Incorporating morphometry into biopsy analysis of early‐stage MF may also provide better diagnostic and prognostic accuracy.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
COVID‐19 Outcomes and Vaccination Response Among Patients With Psoriasis Receiving Biologics
Background: Biologic therapy in psoriasis raises concerns regarding COVID‐19 infection risk and vaccine response, yet real‐world data remain limited. Objective: To evaluate COVID‐19 infection rates, clinical severity, and vaccination response among biologic‐treated patients with psoriasis during the COVID‐19 pandemic. Methods: This cohort study included 12,306 patients with psoriasis followed at a tertiary medical center between March 2020 and May 2023. Primary outcomes included estimated SARS‐CoV‐2 infection rates, hospitalization, ICU admission, mortality, and a composite severe COVID‐19 outcome (hospitalization, ICU admission, or death). Results: Based on national seroprevalence‐adjusted rates, infection occurred in 673 of 962 biologic‐treated patients (70.0%) and 7657 of 11,344 nonbiologic patients (67.5%) ( p = 0.18). Hospitalization was more frequent among biologic‐treated patients (45.2% vs 25.1%; p < 0.001), while ICU admission rates were comparable (2.6% vs 2.0%; p = 0.41). Mortality was significantly lower in the biologic group (6.3% vs 12.1%; p < 0.001). Conclusions: Biologic therapy in psoriasis was not associated with increased susceptibility to SARS‐CoV‐2 infection or impaired vaccine response.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessCOVID‐19 Outcomes and Vaccination Response Among Patients With Psoriasis Receiving Biologics
Background: Biologic therapy in psoriasis raises concerns regarding COVID‐19 infection risk and vaccine response, yet real‐world data remain limited. Objective: To evaluate COVID‐19 infection rates, clinical severity, and vaccination response among biologic‐treated patients with psoriasis during the COVID‐19 pandemic. Methods: This cohort study included 12,306 patients with psoriasis followed at a tertiary medical center between March 2020 and May 2023. Primary outcomes included estimated SARS‐CoV‐2 infection rates, hospitalization, ICU admission, mortality, and a composite severe COVID‐19 outcome (hospitalization, ICU admission, or death). Results: Based on national seroprevalence‐adjusted rates, infection occurred in 673 of 962 biologic‐treated patients (70.0%) and 7657 of 11,344 nonbiologic patients (67.5%) ( p = 0.18). Hospitalization was more frequent among biologic‐treated patients (45.2% vs 25.1%; p < 0.001), while ICU admission rates were comparable (2.6% vs 2.0%; p = 0.41). Mortality was significantly lower in the biologic group (6.3% vs 12.1%; p < 0.001). Conclusions: Biologic therapy in psoriasis was not associated with increased susceptibility to SARS‐CoV‐2 infection or impaired vaccine response.
- Open Access
- 15 July 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (5) , 978-986
Genetic, immunological and clinical assessment of isolated chronic recalcitrant dermatophytosis: a prospective study
Background: Chronic recalcitrant dermatophyte infection (CRDI) remains poorly understood, with limited research on its genetic, immunological and treatment aspects. Objectives: To investigate the genetic and immunological profiles, clinical characteristics and treatment outcomes in otherwise healthy patients with CRDI. Methods: This was a prospective study of patients with isolated superficial dermatophyte infections persisting for > 5 years and refractory to at least three oral antifungal agents. Whole-exome sequencing, interleukin (IL)-17 quantification and lymphocyte subset analysis were performed. Results: Of 5910 patients with superficial cutaneous fungal infections, 11 (10 men; 91%) with a mean (SD) disease duration of 26.4 (8.7) years were included in this study. All patients presented with extensive dermatophytosis, involving a mean (SD) of 5.6 (1.4) skin and nail sites. Immune alterations were identified in 55% (n = 6/11) of the patients, including three with monogenic immunodeficiency mutations (CARD9 and FOXN1), one with acquired immunodeficiency (Good syndrome) and two with isolated IL-17 deficiencies. Most patients (n = 10/11) showed a partial clinical response to continuous oral antifungal therapy, while only one patient remained a complete responder after discontinuing treatment. Conclusions: CRDI is a rare condition in patients with superficial cutaneous fungal infections. Genetic and immunological evaluation for immunodeficiency should be considered in patients with CRDI. Management may require prolonged or lifelong oral antifungal therapy.
- 15 July 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (5) , 978-986
Open AccessGenetic, immunological and clinical assessment of isolated chronic recalcitrant dermatophytosis: a prospective study
Background: Chronic recalcitrant dermatophyte infection (CRDI) remains poorly understood, with limited research on its genetic, immunological and treatment aspects. Objectives: To investigate the genetic and immunological profiles, clinical characteristics and treatment outcomes in otherwise healthy patients with CRDI. Methods: This was a prospective study of patients with isolated superficial dermatophyte infections persisting for > 5 years and refractory to at least three oral antifungal agents. Whole-exome sequencing, interleukin (IL)-17 quantification and lymphocyte subset analysis were performed. Results: Of 5910 patients with superficial cutaneous fungal infections, 11 (10 men; 91%) with a mean (SD) disease duration of 26.4 (8.7) years were included in this study. All patients presented with extensive dermatophytosis, involving a mean (SD) of 5.6 (1.4) skin and nail sites. Immune alterations were identified in 55% (n = 6/11) of the patients, including three with monogenic immunodeficiency mutations (CARD9 and FOXN1), one with acquired immunodeficiency (Good syndrome) and two with isolated IL-17 deficiencies. Most patients (n = 10/11) showed a partial clinical response to continuous oral antifungal therapy, while only one patient remained a complete responder after discontinuing treatment. Conclusions: CRDI is a rare condition in patients with superficial cutaneous fungal infections. Genetic and immunological evaluation for immunodeficiency should be considered in patients with CRDI. Management may require prolonged or lifelong oral antifungal therapy.
- Open Access
A high-throughput zebrafish screen identifies novel candidate treatments for Kaposiform Lymphangiomatosis (KLA)
Kaposiform Lymphangiomatosis (KLA) is a rare, aggressive, and incurable disease caused by a somatic activating NRAS mutation (p.Q61R) in lymphatic endothelial cells (LECs). The development of new therapeutic avenues is hampered by the lack of animal models faithfully replicating the clinical manifestations of KLA. Here, we established a novel zebrafish model of KLA by driving conditional expression of the human NRAS mutation in venous and lymphatic ECs. We find that mutant embryos recapitulated clinical features of KLA, including pericardial edema and a dilated thoracic duct, and that the phenotypes were reverted by Trametinib, a MEK inhibitor used for KLA treatment. We further leverage this model in combination with an AI-based high-throughput drug screening platform to search for small compounds selectively reverting the mutant phenotypes and identify Cabozantinib, an FDA-approved tyrosine kinase inhibitor, and GSK690693, a competitive pan-Akt kinase inhibitor, as leading hits. Finally, we test these drugs in cultured cells derived from KLA patient and demonstrate their ability to normalize LEC sprouting and block NRAS downstream pathways, underscoring the potential of GSK690693 and Cabozantinib as potential KLA treatments. Overall, our novel zebrafish model provides a valuable tool for research into the etiology of KLA and for identifying new therapeutic avenues.
Open AccessA high-throughput zebrafish screen identifies novel candidate treatments for Kaposiform Lymphangiomatosis (KLA)
Kaposiform Lymphangiomatosis (KLA) is a rare, aggressive, and incurable disease caused by a somatic activating NRAS mutation (p.Q61R) in lymphatic endothelial cells (LECs). The development of new therapeutic avenues is hampered by the lack of animal models faithfully replicating the clinical manifestations of KLA. Here, we established a novel zebrafish model of KLA by driving conditional expression of the human NRAS mutation in venous and lymphatic ECs. We find that mutant embryos recapitulated clinical features of KLA, including pericardial edema and a dilated thoracic duct, and that the phenotypes were reverted by Trametinib, a MEK inhibitor used for KLA treatment. We further leverage this model in combination with an AI-based high-throughput drug screening platform to search for small compounds selectively reverting the mutant phenotypes and identify Cabozantinib, an FDA-approved tyrosine kinase inhibitor, and GSK690693, a competitive pan-Akt kinase inhibitor, as leading hits. Finally, we test these drugs in cultured cells derived from KLA patient and demonstrate their ability to normalize LEC sprouting and block NRAS downstream pathways, underscoring the potential of GSK690693 and Cabozantinib as potential KLA treatments. Overall, our novel zebrafish model provides a valuable tool for research into the etiology of KLA and for identifying new therapeutic avenues.
- 17 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (9) , 1788-1798.e7
Primary Melanoma miRNA Trafficking Induces Lymphangiogenesis
- 17 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (9) , 1788-1798.e7
Primary Melanoma miRNA Trafficking Induces Lymphangiogenesis
- 9 December 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (6) , 933-943.e8
Altered RNA Editing in Atopic Dermatitis Highlights the Role of Double-Stranded RNA for Immune Surveillance
- 9 December 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (6) , 933-943.e8
Altered RNA Editing in Atopic Dermatitis Highlights the Role of Double-Stranded RNA for Immune Surveillance
- Open Access
- 29 September 2022
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 102, adv00784
Illness Perception Regarding Early-stage Mycosis Fungoides among Dermatologists: A Multi-centre Cross-sectional Study
Early-stage mycosis fungoides is a rare cutaneous T-cell lymphoma with a good prognosis. Data regarding patients’ illness perception of mycosis fungoides are accumulating. However, investigating the dermatologists’ viewpoint is also essential, as it shapes the therapeutic relationship and doctor–patient communication. The aim of this study was to investigate the aspects of dermatologists’ illness perception towards early-stage mycosis fungoides and the way they present it to patients. Twenty-five dermatology residents and 55 attending physicians from all Israeli dermatology departments and the community completed the study questionnaires online. Dermatologists viewed mycosis fungoides as a chronic disease, causing a moderate emotional burden. In contrast to previously published data regarding patients’ illness perception, dermatologists demonstrated dominancy in the notion that patients were able to control their disease. Most dermatologists thought that patients perceived mycosis fungoides as an indolent lymphoma that causes anxiety. Dermatologists used a high diversity of themes when presenting mycosis fungoides to patients. The differences between the residents’ and attending physicians’ perceptions were minimal. Dermatologists have a kaleidoscope of views regarding the way they perceive mycosis fungoides, the way they think patients perceive it, and the way they communicate with patients. Maintaining patient-centred communication enables dermatologists to identify these gaps and view mycosis fungoides from their patients’ perspective.
- 29 September 2022
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 102, adv00784
Open AccessIllness Perception Regarding Early-stage Mycosis Fungoides among Dermatologists: A Multi-centre Cross-sectional Study
Early-stage mycosis fungoides is a rare cutaneous T-cell lymphoma with a good prognosis. Data regarding patients’ illness perception of mycosis fungoides are accumulating. However, investigating the dermatologists’ viewpoint is also essential, as it shapes the therapeutic relationship and doctor–patient communication. The aim of this study was to investigate the aspects of dermatologists’ illness perception towards early-stage mycosis fungoides and the way they present it to patients. Twenty-five dermatology residents and 55 attending physicians from all Israeli dermatology departments and the community completed the study questionnaires online. Dermatologists viewed mycosis fungoides as a chronic disease, causing a moderate emotional burden. In contrast to previously published data regarding patients’ illness perception, dermatologists demonstrated dominancy in the notion that patients were able to control their disease. Most dermatologists thought that patients perceived mycosis fungoides as an indolent lymphoma that causes anxiety. Dermatologists used a high diversity of themes when presenting mycosis fungoides to patients. The differences between the residents’ and attending physicians’ perceptions were minimal. Dermatologists have a kaleidoscope of views regarding the way they perceive mycosis fungoides, the way they think patients perceive it, and the way they communicate with patients. Maintaining patient-centred communication enables dermatologists to identify these gaps and view mycosis fungoides from their patients’ perspective.
- 23 September 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (1) , 184-193
Changing spectrum of hair and scalp disorders over the last decade in a tertiary medical centre
Background: Hair‐ and scalp‐related disorders (HSRDs) encompass a wide range of conditions that affect people of all ages.Objective: To evaluate the workload and trends in HSRDs at an outpatient dermatological clinic in a tertiary medical centre over a 10‐year period.Methods: Medical records for HSRD visits to the outpatient dermatology clinic at the Sheba Medical Center, an Israeli tertiary care center, were reviewed between 1 January, 2010 and 31 December, 2020.Results: There were 10,396 HSRD visits with a new‐to‐follow‐up visit ratio of 1:1.9. The annual number of HSRD visits, as well as their proportion out of all dermatological outpatient visits, have increased from 295 (1.24%) in 2010 to 1726 (9.44%) in 2020. The patients' mean age was 35.3 years (women 39.5 years, men 28.8 years), age range 1–87 years. Over the decade, there was a growing predominance of women with an average female‐to‐male ratio of 2:1. The winter season accounted for 28.7% of annual visits, followed by the autumn (25.6%), summer (24.3%) and spring (21.4%). The most prevalent HSRDs included androgenetic alopecia (30.6%), alopecia areata (19.3%), telogen effluvium (15.4%), non‐scarring folliculitis (15.4%), seborrheic dermatitis (14.9%), lichen planopilaris (7.1%) and folliculitis decalvans (6.6%). Androgenetic alopecia demonstrated the highest increase over the decade examined (from 17% to 32%).Conclusion: HSRDs account for a significant percentage of visits at a tertiary dermatology outpatient clinic. The number of HSRD visits has increased annually over the past decade. The recent advancement in diagnosis and treatment may account, at least in part, for the growing burden of HSRDs within dermatological ambulatory care.
- 23 September 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (1) , 184-193
Changing spectrum of hair and scalp disorders over the last decade in a tertiary medical centre
Background: Hair‐ and scalp‐related disorders (HSRDs) encompass a wide range of conditions that affect people of all ages.Objective: To evaluate the workload and trends in HSRDs at an outpatient dermatological clinic in a tertiary medical centre over a 10‐year period.Methods: Medical records for HSRD visits to the outpatient dermatology clinic at the Sheba Medical Center, an Israeli tertiary care center, were reviewed between 1 January, 2010 and 31 December, 2020.Results: There were 10,396 HSRD visits with a new‐to‐follow‐up visit ratio of 1:1.9. The annual number of HSRD visits, as well as their proportion out of all dermatological outpatient visits, have increased from 295 (1.24%) in 2010 to 1726 (9.44%) in 2020. The patients' mean age was 35.3 years (women 39.5 years, men 28.8 years), age range 1–87 years. Over the decade, there was a growing predominance of women with an average female‐to‐male ratio of 2:1. The winter season accounted for 28.7% of annual visits, followed by the autumn (25.6%), summer (24.3%) and spring (21.4%). The most prevalent HSRDs included androgenetic alopecia (30.6%), alopecia areata (19.3%), telogen effluvium (15.4%), non‐scarring folliculitis (15.4%), seborrheic dermatitis (14.9%), lichen planopilaris (7.1%) and folliculitis decalvans (6.6%). Androgenetic alopecia demonstrated the highest increase over the decade examined (from 17% to 32%).Conclusion: HSRDs account for a significant percentage of visits at a tertiary dermatology outpatient clinic. The number of HSRD visits has increased annually over the past decade. The recent advancement in diagnosis and treatment may account, at least in part, for the growing burden of HSRDs within dermatological ambulatory care.
- Open Access
- 1 January 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (1) , 27-33
Percepção da doença, estratégias de enfrentamento e qualidade de vida na fase inicial da micose fungoide
- 1 January 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 96 (1) , 27-33
Open AccessPercepção da doença, estratégias de enfrentamento e qualidade de vida na fase inicial da micose fungoide
- Open Access
- 1 January 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (1) , 27-33
Illness perception, coping, and quality of life in early-stage Mycosis fungoides
- 1 January 2021
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 96 (1) , 27-33
Open AccessIllness perception, coping, and quality of life in early-stage Mycosis fungoides